RT-PCR detection of breast cancer cells in sentinel lymph modes.

A. Kataoka, Masaki Mori, N. Sadanaga, H. Ueo, K. Tsuji, Y. Rai, G. F. Barnard, K. Sugimachi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Sentinel lymph node (SLN) biopsy is being evaluated in breast cancer patients to improve detection of metastases and to guide therapy with minimal morbidity. The aim of this study was to increase the sensitivity of tumor cell detection in SLNs using superior reverse transcription polymerase chain reaction (RT-PCR) for carcinoembryonic antigen (CEA) and mammaglobin (MMG) analysis rather than current methods which fail to identify clinically relevant disease in many patients. In seventy stage I and II breast cancer patients dye-guided lymph node mapping was performed and the SLNs were divided alternately for RT-PCR or hematoxylin and eosin staining (H&E). RT-PCR and H&E diagnosis of SLNs were compared. SLNs were identified in 66/70 (94.3%) patients. Seventeen patients (26. 2%) had histological metastasis in SLNs. CEA was expressed in 25.0% of 48 patients with H&E negative SLNs, and MMG was expressed in 20. 8%. SLNs could predict axillary lymph node status with 95.4% accuracy and 6.3% false negative rate by H&E. Moreover, RT-PCR improved these to 98.5% and 2.8%, respectively. SLN diagnosis using RT-PCR is a powerful and sensitive method, which increases the accuracy of clinical staging and may provide more informed choices for appropriate therapeutic management of breast cancer patients.

Original languageEnglish
Pages (from-to)1147-1152
Number of pages6
JournalInternational journal of oncology
Volume16
Issue number6
Publication statusPublished - Jan 1 2000

Fingerprint

Lymph
Reverse Transcription
Breast Neoplasms
Polymerase Chain Reaction
Carcinoembryonic Antigen
Lymph Nodes
Neoplasm Metastasis
Sentinel Lymph Node Biopsy
Hematoxylin
Eosine Yellowish-(YS)
cyhalothrin
Coloring Agents
Staining and Labeling
Morbidity
Therapeutics
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kataoka, A., Mori, M., Sadanaga, N., Ueo, H., Tsuji, K., Rai, Y., ... Sugimachi, K. (2000). RT-PCR detection of breast cancer cells in sentinel lymph modes. International journal of oncology, 16(6), 1147-1152.

RT-PCR detection of breast cancer cells in sentinel lymph modes. / Kataoka, A.; Mori, Masaki; Sadanaga, N.; Ueo, H.; Tsuji, K.; Rai, Y.; Barnard, G. F.; Sugimachi, K.

In: International journal of oncology, Vol. 16, No. 6, 01.01.2000, p. 1147-1152.

Research output: Contribution to journalArticle

Kataoka, A, Mori, M, Sadanaga, N, Ueo, H, Tsuji, K, Rai, Y, Barnard, GF & Sugimachi, K 2000, 'RT-PCR detection of breast cancer cells in sentinel lymph modes.', International journal of oncology, vol. 16, no. 6, pp. 1147-1152.
Kataoka A, Mori M, Sadanaga N, Ueo H, Tsuji K, Rai Y et al. RT-PCR detection of breast cancer cells in sentinel lymph modes. International journal of oncology. 2000 Jan 1;16(6):1147-1152.
Kataoka, A. ; Mori, Masaki ; Sadanaga, N. ; Ueo, H. ; Tsuji, K. ; Rai, Y. ; Barnard, G. F. ; Sugimachi, K. / RT-PCR detection of breast cancer cells in sentinel lymph modes. In: International journal of oncology. 2000 ; Vol. 16, No. 6. pp. 1147-1152.
@article{c9e34436e309481881c5f5319fbd6680,
title = "RT-PCR detection of breast cancer cells in sentinel lymph modes.",
abstract = "Sentinel lymph node (SLN) biopsy is being evaluated in breast cancer patients to improve detection of metastases and to guide therapy with minimal morbidity. The aim of this study was to increase the sensitivity of tumor cell detection in SLNs using superior reverse transcription polymerase chain reaction (RT-PCR) for carcinoembryonic antigen (CEA) and mammaglobin (MMG) analysis rather than current methods which fail to identify clinically relevant disease in many patients. In seventy stage I and II breast cancer patients dye-guided lymph node mapping was performed and the SLNs were divided alternately for RT-PCR or hematoxylin and eosin staining (H&E). RT-PCR and H&E diagnosis of SLNs were compared. SLNs were identified in 66/70 (94.3{\%}) patients. Seventeen patients (26. 2{\%}) had histological metastasis in SLNs. CEA was expressed in 25.0{\%} of 48 patients with H&E negative SLNs, and MMG was expressed in 20. 8{\%}. SLNs could predict axillary lymph node status with 95.4{\%} accuracy and 6.3{\%} false negative rate by H&E. Moreover, RT-PCR improved these to 98.5{\%} and 2.8{\%}, respectively. SLN diagnosis using RT-PCR is a powerful and sensitive method, which increases the accuracy of clinical staging and may provide more informed choices for appropriate therapeutic management of breast cancer patients.",
author = "A. Kataoka and Masaki Mori and N. Sadanaga and H. Ueo and K. Tsuji and Y. Rai and Barnard, {G. F.} and K. Sugimachi",
year = "2000",
month = "1",
day = "1",
language = "English",
volume = "16",
pages = "1147--1152",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - RT-PCR detection of breast cancer cells in sentinel lymph modes.

AU - Kataoka, A.

AU - Mori, Masaki

AU - Sadanaga, N.

AU - Ueo, H.

AU - Tsuji, K.

AU - Rai, Y.

AU - Barnard, G. F.

AU - Sugimachi, K.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Sentinel lymph node (SLN) biopsy is being evaluated in breast cancer patients to improve detection of metastases and to guide therapy with minimal morbidity. The aim of this study was to increase the sensitivity of tumor cell detection in SLNs using superior reverse transcription polymerase chain reaction (RT-PCR) for carcinoembryonic antigen (CEA) and mammaglobin (MMG) analysis rather than current methods which fail to identify clinically relevant disease in many patients. In seventy stage I and II breast cancer patients dye-guided lymph node mapping was performed and the SLNs were divided alternately for RT-PCR or hematoxylin and eosin staining (H&E). RT-PCR and H&E diagnosis of SLNs were compared. SLNs were identified in 66/70 (94.3%) patients. Seventeen patients (26. 2%) had histological metastasis in SLNs. CEA was expressed in 25.0% of 48 patients with H&E negative SLNs, and MMG was expressed in 20. 8%. SLNs could predict axillary lymph node status with 95.4% accuracy and 6.3% false negative rate by H&E. Moreover, RT-PCR improved these to 98.5% and 2.8%, respectively. SLN diagnosis using RT-PCR is a powerful and sensitive method, which increases the accuracy of clinical staging and may provide more informed choices for appropriate therapeutic management of breast cancer patients.

AB - Sentinel lymph node (SLN) biopsy is being evaluated in breast cancer patients to improve detection of metastases and to guide therapy with minimal morbidity. The aim of this study was to increase the sensitivity of tumor cell detection in SLNs using superior reverse transcription polymerase chain reaction (RT-PCR) for carcinoembryonic antigen (CEA) and mammaglobin (MMG) analysis rather than current methods which fail to identify clinically relevant disease in many patients. In seventy stage I and II breast cancer patients dye-guided lymph node mapping was performed and the SLNs were divided alternately for RT-PCR or hematoxylin and eosin staining (H&E). RT-PCR and H&E diagnosis of SLNs were compared. SLNs were identified in 66/70 (94.3%) patients. Seventeen patients (26. 2%) had histological metastasis in SLNs. CEA was expressed in 25.0% of 48 patients with H&E negative SLNs, and MMG was expressed in 20. 8%. SLNs could predict axillary lymph node status with 95.4% accuracy and 6.3% false negative rate by H&E. Moreover, RT-PCR improved these to 98.5% and 2.8%, respectively. SLN diagnosis using RT-PCR is a powerful and sensitive method, which increases the accuracy of clinical staging and may provide more informed choices for appropriate therapeutic management of breast cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0034201297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034201297&partnerID=8YFLogxK

M3 - Article

C2 - 10811988

AN - SCOPUS:0034201297

VL - 16

SP - 1147

EP - 1152

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -